600511 国药股份
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)11.19412.15714.31114.55114.482
总资产报酬率 ROA (%)5.5765.9376.9166.8176.630
投入资产回报率 ROIC (%)8.7139.45311.29411.48711.621

边际利润分析
销售毛利率 (%)6.5947.1068.0318.4017.814
营业利润率 (%)4.9975.2925.9255.9235.267
息税前利润/营业总收入 (%)4.9145.1105.6445.8445.222
净利润/营业总收入 (%)3.9824.2094.6974.6794.150

收益指标分析
经营活动净收益/利润总额(%)80.19482.66385.36584.82886.605
价值变动净收益/利润总额(%)21.80018.69012.61610.84911.590
营业外收支净额/利润总额(%)-0.828-0.897-0.460-0.262-0.101

偿债能力分析
流动比率 (X)2.0772.0432.0352.0221.930
速动比率 (X)1.7401.7101.7501.7311.654
资产负债率 (%)44.64245.67445.97446.43748.749
带息债务/全部投入资本 (%)16.15819.17815.01216.49814.208
股东权益/带息债务 (%)492.994396.060531.600472.573563.460
股东权益/负债合计 (%)113.238107.364105.737103.38493.595
利息保障倍数 (X)-117.852-38.006-22.238-92.200-132.292

营运能力分析
应收账款周转天数 (天)86.04275.73753.26045.32643.226
存货周转天数 (天)37.27134.14930.24231.23727.584